Prevalence of adverse drug reactions to highly active antiretroviral therapy (HAART) among HIV positive patients in imam khomeini hospital of tehran, Iran

Infectious Disorders - Drug Targets

Volumn 17, Issue 2, 2017, Pages 116-119

  Koochak, Hamid E ^a   Babaei, Azita ^a   Pourdast, Alia ^a   Golrokhy, Raheleh ^a   Ra Soolinejad, Mehrnaz ^a   Khodaei, Sepideh ^a   Moghadam, Saeed R J ^b   Taheri, Reza R ^b   Alinaghi, Seyed Ahmad Seyed ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse drug reaction; Antiretroviral therapy; Clinical; HIV; Paraclinical; Prevalence

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CEREBRAL TOXOPLASMOSIS; CROSS-SECTIONAL STUDY; CYTOMEGALOVIRUS; DRUG SUBSTITUTION; FATIGUE; FEMALE; HEADACHE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INTERVIEW; IRAN; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MYALGIA; NAUSEA; PARALYSIS; PARESTHESIA; PNEUMOCYSTIS CARINII; PREVALENCE; RASH; SLEEP DISORDER; THROMBOCYTOPENIA; TUBERCULOSIS; VOMITING; WEIGHT REDUCTION; ADOLESCENT; AIDS RELATED COMPLEX; CD4 LYMPHOCYTE COUNT; CHILD; COMPLICATION; HEPATITIS C; MICROBIOLOGY; PATIENT COMPLIANCE; PRESCHOOL CHILD; TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; IRAN; MALE; MIDDLE AGED; PREVALENCE; TREATMENT ADHERENCE AND COMPLIANCE; TUBERCULOSIS; YOUNG ADULT;

EID: 85027870159     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526517666170117111350     Document Type: Article

References (16)

1. Hammer, S.M.; Katzenstein, D.A.; Hughes, M.D. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 0 to 500 per cubic millimetre. N. Engl. J. Med., 1996, 335, 1081-1090.
2. Mocroft, A. Changing patterns of mortality across Europe in patients infected with HIV EuroSIDA Study Group. Lancet, 1998, 352 (9142), 1725-1730.
3. Andrew, Carr, M.D.; David, A.; Cooper, A.B. Adverse effects of antiretroviral therapy. Lancet, 2000, 356 (9239), 1423-1430.
4. Axelsson, J.M.; Hallager, S.; Barfod, T.S. Antiretroviral therapy adherence strategies used by patients of a large HIV clinic in Lesotho. J. Health Popul. Nutr., 2015, 33(1), 10.
5. Glidden, D.V.; Amico, K.R.; Liu, A.Y.; Hosek, S.G.; Anderson, P.L.; Buchbinder, S.P. Symptoms, Side Effects and adherence in the iPrEx open-label extension. Clin. Infect. Dis., 62(9), 1172-1177.
6. Rochster, H.; Dieterich, D.; Bozzette, S. Toxicity of combined ganciclovir and zidovudine for cytomegal-ovirus disease associated with AIDS: An AIDS Clinical Trials Group study. Ann. Intern. Med., 1990, 113, 111-117.
7. Boubaker, K.; Sudre, P.; Bally, F. Changes in renal function associated with indinavir. AIDS, 1998, 12, 249-254.
8. Brodie, S.B.; Keller, M.J.; Ewenstein, B.M.; Sax, P.E. Variations in incidence of indinavir-associated neph-rolithiasis among HIV-positive patients. AIDS, 1998, 12, 2433-2438.
9. Danner, S.A.; Carr, A.; Leonard, J. Safety, pharmacokinetics and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl. J. Med., 1995, 333, 1528-1533.
10. SeyedAlinaghi, S.A.; Sudhinaraset, M.; Koochak, H.E.; Paydary, K.; Emamzadeh-Fard, S.; Khodaei, S.; Sardashti, S. CHIVR., ed.; Bentham Science Publish-ers: U.A.E, 2016, 2, pp. 268-278.
11. SeyedAlinaghi SA. Comparison of TB/HIV indicators after implementation of clinical protocol for TB and TB/HIV management in Iranian prisons [dissertation]. Tehran University of Medical Sciences; 2016.
12. Mockenhaupt, M.; Bouwes-Bavnick, J.N.; Naldi, L.; Viboud, C.; Roujeau, J.C. nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS, 2001, 15,1843-1848.
13. Sulkowski, M.S.; Thomas, D.L.; Chaisson, R.E.; Moore, R.D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA, 2000, 283(1), 74-80.
14. Modayil, R.R.; Harugeri, A.; Parthasarathi, G.; Ramesh, M.; Prasad, R.; Naik, V.; Giriyapura, V. Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. Pharmacoepidemiol. Drug Saf., 2010, 19(3), 247-255.
15. Anwikar, S.R.; Bandekar, M.S.; Smrati, B.; Pazare, A.P.; Tatke, P.A.; Kshirsagar, N.A. HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India. Int. J. Risk Saf. Med., 2011, 23(3), 163-169.
16. Srikanth, B.A.; Babu, S.C.; Yadav, H.N.; Jain, S.K. Incidence of adverse drug reaction in human immune deficiency virus-positive patients using highly active antiretroviral therapy. J. Adv. Pharm. Tech. Res., 2012, 3(1), 62-67.